Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitis
read at Endpoints ↗Negative readoutNegative
Evommune reported that its experimental small-molecule antagonist of the MRGPRX2 receptor did not meet its primary endpoints in a Phase 2b study in patients with atopic dermatitis.
The study, conducted this summer, was the company’s second mid-stage trial of the Dermira-derived compound to end in a negative outcome.
The failure highlights the challenges of developing MRGPRX2-targeted therapies for inflammatory skin conditions and may delay Evommune’s timeline for advancing the drug.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Evommune's MRGPRX2 antagonist flunks its second I&I trial this summer”
read at Endpoints ↗77 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that